G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 115 filers reported holding G1 THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 1.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,887,740 | +171.2% | 827,956 | +413.9% | 0.00% | – |
| Q1 2024 | $695,978 | +41.6% | 161,106 | 0.0% | 0.00% | – |
| Q4 2023 | $491,373 | +111.8% | 161,106 | 0.0% | 0.00% | – |
| Q3 2023 | $231,993 | -42.2% | 161,106 | 0.0% | 0.00% | – |
| Q2 2023 | $401,154 | -24.5% | 161,106 | -18.7% | 0.00% | – |
| Q1 2023 | $531,085 | -72.8% | 198,166 | -44.9% | 0.00% | – |
| Q4 2022 | $1,951,932 | -90.3% | 359,472 | -77.8% | 0.00% | -100.0% |
| Q3 2022 | $20,214,000 | +2779.5% | 1,618,381 | +1038.1% | 0.00% | – |
| Q2 2022 | $702,000 | -97.5% | 142,206 | -96.1% | 0.00% | -100.0% |
| Q1 2022 | $27,944,000 | -36.4% | 3,676,814 | -14.5% | 0.00% | -50.0% |
| Q4 2021 | $43,919,000 | -25.3% | 4,301,613 | -1.9% | 0.00% | -33.3% |
| Q3 2021 | $58,828,000 | -3.2% | 4,383,612 | +58.2% | 0.00% | 0.0% |
| Q2 2021 | $60,797,000 | -7.5% | 2,771,047 | +1.5% | 0.00% | -25.0% |
| Q1 2021 | $65,706,000 | +41.6% | 2,730,936 | +5.9% | 0.00% | +33.3% |
| Q4 2020 | $46,411,000 | +69.9% | 2,579,819 | +9.1% | 0.00% | +50.0% |
| Q3 2020 | $27,319,000 | -17.3% | 2,365,259 | +73.8% | 0.00% | 0.0% |
| Q2 2020 | $33,016,000 | +118.3% | 1,360,913 | -0.9% | 0.00% | +100.0% |
| Q1 2020 | $15,127,000 | -58.4% | 1,372,714 | -0.2% | 0.00% | -50.0% |
| Q4 2019 | $36,350,000 | +39.0% | 1,375,328 | +19.8% | 0.00% | 0.0% |
| Q3 2019 | $26,149,000 | -36.2% | 1,147,895 | -14.1% | 0.00% | -33.3% |
| Q2 2019 | $40,961,000 | +105.2% | 1,335,960 | +11.1% | 0.00% | +50.0% |
| Q1 2019 | $19,959,000 | -14.0% | 1,202,361 | -0.8% | 0.00% | 0.0% |
| Q4 2018 | $23,216,000 | -45.8% | 1,212,339 | +47.9% | 0.00% | -33.3% |
| Q3 2018 | $42,857,000 | +4.5% | 819,602 | -13.1% | 0.00% | 0.0% |
| Q2 2018 | $41,007,000 | +398.8% | 943,550 | +325.2% | 0.00% | +200.0% |
| Q1 2018 | $8,221,000 | +254.5% | 221,895 | +89.9% | 0.00% | – |
| Q4 2017 | $2,319,000 | +96.0% | 116,859 | +145.4% | 0.00% | – |
| Q3 2017 | $1,183,000 | – | 47,618 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Boxer Capital, LLC | 629,179 | $12,483,000 | 2.28% |
| Cormorant Asset Management, LP | 897,505 | $17,806,000 | 1.86% |
| EMERALD ADVISERS, LLC | 721,438 | $14,313,000 | 0.55% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 580,857 | $11,524,000 | 0.46% |
| Virtus ETF Advisers LLC | 17,647 | $350,000 | 0.44% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 39,000 | $773,000 | 0.27% |
| RA Capital Management | 159,780 | $3,170,000 | 0.26% |
| Rock Springs Capital Management LP | 214,500 | $4,256,000 | 0.19% |
| Hillhouse Capital Management | 450,000 | $8,928,000 | 0.15% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 86,405 | $1,714,000 | 0.06% |